Company intelligence / Profile preview

BioCentriq

Ownership: Private
Development stage: Other

Overview

BioCentriq is a leading CDMO specializing in process development and GMP clinical manufacturing for autologous/allogeneic cell therapies, gene therapies, monoclonal antibodies, proteins, and vaccines. It has established quality systems for various cell/vector types and supports early to mid-stage clinical programs. Its LEAP™ platform accelerates manufacturing timelines for advanced therapies. No direct clinical results are reported as it does not develop proprietary therapeutics.

Therapeutic areas: Other
Modalities: Cell therapyGene therapyMonoclonal antibodyProteinVaccine
Industry: Contract Manufacturing Organization

Partnerships

Terumo Blood and Cell TechnologiesCytivaPremier Research

Beyond the preview

Go deeper on BioCentriq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCentriq.